Product Name :DARPP-32 (phospho-T34) polyclonal antibody
Reactivity :Human,Mouse,Rat
Application_all :WB: 1:500~1:1000
IHC: 1:50~1:200
Background :Dopaminergic signaling pathways, which are essential for multiple brain functions, are abnormal in several neurological disorders, such as schizophrenia, Parkinson’s disease and drug abuse. DARPP-32 (for dopamine and adenosine 3’,5’-monophosphate-regulated phosphoprotein of 32 kDa) is abundant in neurons that receive dopaminergic input. Activation of PKA and the consequent phosphorylation of DARPP-32 on threonine occurs in response to dopamine acting upon D1-like receptors. Dopamine interaction with D2-like receptors results in the inhibition of PKA activation, the activation of protein phosphatase 2B and the consequent dephosphorylation of DARPP-32. Neurotransmitters other than dopamine may also be able to stimulate the phosphorylation or dephosphorylation of DARPP-32. Phosphorylated DARPP-32 is a potent inhibitor of PP-1.
Product :Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Purification&Purity :The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Storage&Stability :Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :p-DARPP-32 (T34) polyclonal antibody detects endogenous levels of DARPP-32 protein only when phosphorylated at Thr34.
Note :For research use only, not for use in diagnostic procedure.
Pathway :Neuronal and Glial Cell Marker Atlas,Dopamine Signaling in Parkinson's Disease Plathway,
Alternative Name :Protein phosphatase 1 regulatory subunit 1B; DARPP-32; Dopamine- and cAMP-regulated neuronal phosphoprotein; PPP1R1B; DARPP32
Immunogen :Synthetic phosphopeptide derived from human DARPP-32 around the phosphorylation site of Threonine 34.
Modification :Phosphorylation
